ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene

ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported case...

Full description

Saved in:
Bibliographic Details
Published inJTO clinical and research reports Vol. 4; no. 4; p. 100489
Main Authors Schoepflin, Zachary R., Academia, Emmeline, Osataphan, Soravis A., Rangachari, Deepa, Sharifi, Sheida, VanderLaan, Paul A., Costa, Daniel B.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2023
Elsevier
Subjects
Alectinib
ALK
Case Report
Deletion
Lung cancer
ALK
Deletion
Alectinib
Case report
Lung cancer
Online AccessGet full text

Cover

More Information
Summary:ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported cases with ALK nonkinase domain deletions (between introns and exons 1–19) can display positive results in nonsequencing-based lung cancer diagnostic tests (such as immunohistochemistry) used to screen for more common ALK rearrangements. This case report emphasizes that “ALK-driven” lung cancers should be expanded to encompass those harboring not only ALK rearrangements with other genes but also ALK nonkinase domain deletions.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2023.100489